FDA Approves Blood Test to Screen for Colon Cancer

While Shield detects 83% of colorectal cancers by identifying tumor DNA in the bloodstream, it is less effective for early-stage polyps. Positive results require follow-up colonoscopies for confirmation. This development could significantly impact early detection and mortality rates in colorectal cancer. Read the story from NBC here.